CORT

Corcept Therapeutics Inc

85.86

Oct 23 • 3:59 PM ET -21.64 (-20.13%)

86.98

Aftermarket • 7:58 PM ET +1.12 (1.30%)

Healthcare Biotechnology USA Mid NASD

Oct 23, 12:50 PMGenmab announces positive Phase 3 data for platinum-resistant ovarian cancer drug, a potential rival to Corcept’s Lifyorli

Peers: ASND XERS NBIX BBIO RYTM ACAD EXEL JAZZ HRMY SUPN

| Held by: IJH VTI VB VBK VXF FBT MDY IJK IWP SPMD

Scroll to Statements

Index	-
Market Cap	9.28B
Enterprise Value	8.98B
Income	54.20M
Sales	830.81M
Book/sh	6.54
Cash/sh	2.85
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	730
IPO	Apr 14, 2004

P/E	205.06
Forward P/E	20.01
PEG	0.19
P/S	11.17
P/B	13.13
P/C	30.11
P/FCF	86.81
EV/EBITDA	1018.43
EV/Sales	10.81
Quick Ratio	2.74
Current Ratio	2.83
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	0.42
EPS next Y	4.29
EPS next Q	0.79
EPS this Y	148.33%
EPS next Y	110.75%
EPS next 5Y	104.08%
EPS past 3/5Y	-2.15% -0.84%
Sales past 3/5Y	23.74% 16.56%
EPS Y/Y TTM	-59.24%
Sales Y/Y TTM	16.02%
EPS Q/Q	23.91%
Sales Q/Q	31.74%
Earnings	Jul 29 AMC
EPS/Sales Surpr.	1381.48% 15.83%

Insider Own	11.40%
Insider Trans	-6.58%
Inst Own	76.30%
Inst Trans	2.54%
ROA	6.41%
ROE	8.08%
ROIC	7.60%
Gross Margin	98.30%
Oper. Margin	0.77%
Profit Margin	6.52%
SMA20	-25.13%
SMA50	-25.48%
SMA200	16.74%
Trades

Shs Outstand	107.92M
Shs Float	95.77M
Short Float	8.92%
Short Ratio	7.17
Short Interest	8.54M
52W High	126.38 -32.06%
52W Low	28.66 199.58%
Volatility	8.58% 5.37%
ATR (14)	6.43
RSI (14)	24.28
Beta	0.49
Rel Volume	2.60
Avg Volume	1.19M
Volume	3,098,681

Perf Week	-22.06%
Perf Month	-27.55%
Perf Quarter	-5.77%
Perf Half Y	86.41%
Perf YTD	146.72%
Perf Year	17.65%
Perf 3Y	215.08%
Perf 5Y	358.65%
Perf 10Y	1137.18%
Recom	1.86
Target Price	141.00
Prev Close	107.50
Price	85.86
Change %	-20.13%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-18-26	Resumed	Truist	Buy	$164
Jul-27-26	Downgrade	Wolfe Research	Peer Perform → Underperform	$50
May-13-26	Upgrade	UBS	Neutral → Buy	$72
Mar-26-26	Upgrade	Wolfe Research	Underperform → Peer Perform
Dec-31-25	Downgrade	Wolfe Research	Peer Perform → Underperform	$30
Dec-16-25	Initiated	UBS	Neutral
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Nov-06-23	Upgrade	Truist	Hold → Buy	$29 → $38
Apr-11-23	Initiated	SVB Securities	Market Perform	$25
Apr-04-23	Initiated	Piper Sandler	Overweight	$27
Feb-15-23	Downgrade	Jefferies	Buy → Hold	$35 → $22
Aug-01-22	Downgrade	Truist	Buy → Hold	$30
Jul-27-22	Upgrade	Jefferies	Hold → Buy	$21 → $35
Jun-27-22	Resumed	Canaccord Genuity	Buy	$30 → $34
Feb-02-22	Initiated	Canaccord Genuity	Buy	$30
Jan-28-22	Initiated	Truist	Buy	$30
Aug-05-20	Downgrade	Jefferies	Buy → Hold	$16
Sep-24-19	Initiated	Jefferies	Buy	$20
Sep-06-19	Initiated	H.C. Wainwright	Buy	$18
Feb-04-19	Downgrade	B. Riley FBR	Buy → Neutral	$22 → $12

Show Previous Ratings

Oct-23-26 12:44PM	Genmab stock surges 9% following positive phase 3 ovarian cancer trial results (Investing.com) -20.13%
Oct-20-26 04:00PM	2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes (Business Wire)
Oct-15-26 02:14PM	Why Healthcare Stocks Are Hot When the AI Trade Runs Cold (Barrons.com)
Oct-06-26 04:43PM	Corcept, IBD Stock Of The Day, Setting Up Amid Booming Earnings Growth (Investor's Business Daily)
Sep-23-26 08:00AM	Corcept Announces Planned Leadership Transition (Business Wire)
08:00AM	Loading…
Sep-18-26 08:00AM	Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli (Relacorilant) (Business Wire)
Sep-04-26 07:42PM	BE, P, ILMN Join S&P 500; LNG Misses Out Bloom Energy Stock Gains While Cheniere Energy Slips (Stocktwits)
07:15PM	Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600 (PR Newswire)
Aug-04-26 06:45AM	What IJR's Own History Says About Its Price Today (Trefis)
Aug-03-26 08:01PM	John Hussman's Top Q2 2026 Move: Exiting Corcept Therapeutics Inc at a -1.1% Portfolio Impact (GuruFocus.com)
Jul-31-26 10:51AM	A spot is opening up in the S&P 500, and these stocks are top candidates to fill the void (MarketWatch)
Jul-30-26 01:53PM	These 2 Biotech Stocks Hit New 52-Week Highs Today And CORT Clocked Its Best Day In Nearly 16 Months (Stocktwits) +27.29%
01:01AM	Corcept Therapeutics Inc (CORT) (Q2 2026) Earnings Call Highlights: Record Revenue and ... (GuruFocus.com)
Jul-29-26 05:46PM	Corcept: Q2 Earnings Snapshot (Associated Press)
04:05PM	Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update (Business Wire)
04:05PM	Loading…
Jul-22-26 04:05PM	Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call (Business Wire) +6.36%
Jun-17-26 04:28PM	Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome (Business Wire)
Jun-06-26 04:45PM	Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym (Business Wire)
May-29-26 04:33PM	Corcept Presents New Data at ASCO 2026: Lifyorli Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure (Business Wire)
May-27-26 09:57AM	CORT Stock Hits Highest Levels In 2026 Cushings Syndrome Drug NDA Resubmission Extends 5-Session Rally (Stocktwits) +10.42%
08:00AM	Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushings Syndrome (Business Wire)
May-11-26 01:00PM	John Hussman Exits Qualcomm Inc, Impacting Portfolio by -1.13% (GuruFocus.com)
May-01-26 03:21AM	Corcept Therapeutics Inc (CORT) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com) +10.53%
Apr-30-26 05:23PM	Corcept: Q1 Earnings Snapshot (Associated Press)
04:05PM	Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update (Business Wire)
04:05PM	Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis (Business Wire)
Apr-23-26 04:05PM	Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call (Business Wire)
Apr-21-26 01:09PM	Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026 (Business Wire)
Apr-10-26 04:45PM	Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Mar-28-26 02:45PM	Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session (Business Wire)
02:10PM	Loading…
Mar-26-26 02:10PM	Corcepts first-in-class ovarian cancer drug gains FDA approval (Pharmaceutical Technology)
Mar-25-26 12:43PM	FDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer (Business Wire) +19.66%
Mar-24-26 08:49AM	Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately (PR Newswire)
Mar-18-26 05:35PM	Robbins LLP Urges CORT Stockholders to Contact the Firm for Information About the Class Against Corcept Therapeutics Incorporated (PR Newswire)
09:00AM	Shareholders of Corcept Therapeutics Incorporated Should Contact Levi & Korsinsky Before April 21, 2026 to Discuss Your Rights - CORT (PR Newswire)
Mar-16-26 03:27AM	Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT (PR Newswire)
Mar-12-26 04:32AM	Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT (PR Newswire)
Mar-09-26 02:37AM	Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT (PR Newswire)
Mar-05-26 08:29AM	Corcept's Korlym Drives its 2025 Revenue Surge: What's Ahead? (Zacks)
Feb-27-26 02:54AM	Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT (PR Newswire)
Feb-25-26 09:12AM	Corcept's Q4 Earnings and Revenues Fall Short of Estimates (Zacks)
07:15AM	Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights CORT (Business Wire)
12:01AM	Corcept Therapeutics Inc (CORT) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
Feb-24-26 11:11PM	Corcept Therapeutics Q4 Earnings Call Highlights (MarketBeat)
09:55PM	Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates (Zacks)
05:13PM	Corcept: Q4 Earnings Snapshot (Associated Press Finance)
04:49PM	Corcept (NASDAQ:CORT) Misses Q4 CY2025 Sales Expectations (StockStory)
04:05PM	Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update (Business Wire)
08:06AM	Is Corcept Therapeutics Incorporated (CORT) at an inflection point? (Insider Monkey)
Feb-22-26 10:12PM	Corcept (CORT) Q4 Earnings: What To Expect (StockStory)
Feb-19-26 04:00PM	Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals (Business Wire) -14.01%
01:03PM	Stocks Fall, Oil Hits 7-Month High As Trump Weighs Iran Strike: What's Moving Markets Thursday? (Benzinga)
11:48AM	Corcept Therapeutics Stock Plunges As Court Clears Teva Generic (Benzinga)
Feb-17-26 04:05PM	Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call (Business Wire)
Feb-16-26 12:24PM	FDA-Issued CRL for Relacorilant NDA Leads to Bullish Views Around Corcept Therapeutics (CORT) (Insider Monkey)
Feb-04-26 03:31PM	Lost Money on Corcept Therapeutics Incorporated (CORT)? Possible Fraud - Contact Levi & Korsinsky Today (Newsfile)
Jan-30-26 08:32PM	Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing (Business Wire) -10.63%
Jan-25-26 06:44PM	Corcept Therapeutics (CORT) Climbs 26.6% on Stellar Clinical Trial Result (Insider Monkey)
Jan-23-26 01:55PM	Silver Breaks $101, Intel Stock Plunges 17%: What's Moving Markets Friday? (Benzinga) +6.49%
11:13AM	CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study (Zacks)
08:11AM	Corcept Therapeutics (CORT) Climbs 13.7% on Strong Clinical Trial Results (Insider Monkey)
05:27AM	Novo climbs higher on strong Wegovy pill launch; Terns tweaks leukemia drug deal (BioPharma Dive)
Jan-22-26 04:05PM	Why Former Highflier Corcept Therapeutics Just Surged Again (Investor's Business Daily) +13.74%
03:06PM	Russell 2000 Extends Records, Meta Jumps 5%: What's Moving Markets Thursday? (Benzinga)
01:07PM	Corcepts stock up as relacorilant meets OS goal in Phase III ovarian cancer trial (Clinical Trials Arena)
11:12AM	Corcept Therapeutics Experimental Lead Drug Cuts Death Risk By 35% In Advanced Ovarian Cancer Patients, Stock Jumps (Benzinga)
08:00AM	Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Jan-15-26 08:15AM	Is Corcept Therapeutics Incorporated (CORT) The Most Promising Growth Stock According to Analysts? (Insider Monkey)
06:47AM	One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit (24/7 Wall St.)
Jan-14-26 11:56AM	Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman (PR Newswire)
Jan-09-26 03:16AM	Price Targets Lowered on Corcept Therapeutics (CORT) After FDA Letter (Insider Monkey)
Jan-06-26 12:01PM	Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman (PR Newswire)
Jan-05-26 11:31PM	1 Healthcare Stock to Target This Week and 2 We Turn Down (StockStory) -8.51%
12:16PM	Why Corcept (CORT) Stock Is Trading Lower Today (StockStory)
09:54AM	Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains? (Zacks)
Jan-02-26 11:17AM	The FDA Just Snubbed Corcept Therapeutics. Should You Buy the Dip in CORT Stock or Stay Far Away (Barchart) +9.77%
10:22AM	Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism (Zacks)
08:50AM	Implied Volatility Surging for Corcept Stock Options (Zacks)
07:30AM	Company News for Jan 2, 2026 (Zacks)
Jan-01-26 08:10AM	FDA says it needs additional evidence of effectiveness for Corcept relacorilant (TipRanks)
Dec-31-25 06:41PM	Why Corcept Therapeutics Plummeted by 50% Today (Motley Fool) -50.42% +9.77%
05:00PM	Why Corcept (CORT) Shares Are Falling Today (StockStory)
04:34PM	Stocks Settle Lower on Tech Weakness and Higher Bond Yields (Barchart)
12:31PM	Corcept Therapeutics Shares Plunge 50% After FDA Rejects Blood Pressure Drug (Barrons.com)
10:00AM	Corcept Sinks After FDA Rejects Drug to Treat Hypertension (Bloomberg)
09:57AM	Stocks Slide on Weakness in Megacap Tech Stocks (Barchart)
08:00AM	Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism (Business Wire)
Dec-30-25 06:32AM	Stock Market Today: Stocks Struggling to Finish 2025 on High Note (TheStreet) -12.06%
Dec-23-25 03:51PM	Why Corcept (CORT) Stock Is Trading Lower Today (StockStory)
Dec-21-25 08:56AM	Corcept Therapeutics (CORT): Analyst Says Shares Pricing in Growth, New Launch (Insider Monkey)
Dec-16-25 11:03PM	Corcept (CORT): Buy, Sell, or Hold Post Q3 Earnings? (StockStory) -7.08%
02:05PM	Why Corcept (CORT) Stock Is Down Today (StockStory)
Dec-11-25 07:44AM	Wall Street Firms Tout Corcept Therapeutics Incorporated (CORT) Prospects on Korlym Medication Prospects (Insider Monkey)
Dec-10-25 11:30AM	Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-07-25 10:33PM	Analysts See 70% Upside Potential in Corcept Therapeutics (CORT) Stock (Insider Monkey)
Dec-04-25 11:30AM	Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-01-25 11:04AM	Will Korlym Continue to Drive Corcept's Top Line in 2026? (Zacks)
Nov-26-25 02:59PM	Corcept Therapeutics Incorporated (CORT) Modifies Revenue Guidance while Banking on Cushing Syndrome Treatment for Growth (Insider Monkey)
Nov-12-25 10:34PM	Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Corcept (NASDAQ:CORT) (StockStory)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WILSON JAMES N	Director	Oct 15 '26	Sale	114.81	10,000	1,148,083	1,054,543	Oct 16 06:24 PM
Vieira Roberto Wandenkolk	President, Oncology	Oct 02 '26	Option Exercise	21.63	8,333	180,243	12,279	Oct 05 07:58 PM
Vieira Roberto Wandenkolk	President, Oncology	Oct 02 '26	Sale	116.10	8,333	967,448	3,946	Oct 05 07:58 PM
Lyon Joseph Douglas	See Remarks	Oct 02 '26	Option Exercise	17.18	9,190	157,864	14,873	Oct 05 07:54 PM
Lyon Joseph Douglas	See Remarks	Oct 01 '26	Option Exercise	13.56	810	10,984	6,493	Oct 05 07:54 PM
Lyon Joseph Douglas	See Remarks	Oct 02 '26	Sale	116.13	9,190	1,067,258	5,683	Oct 05 07:54 PM
Lyon Joseph Douglas	See Remarks	Oct 01 '26	Sale	115.40	810	93,473	5,683	Oct 05 07:54 PM
Maduck Sean	See Remarks	Oct 02 '26	Option Exercise	8.27	24,587	203,334	34,525	Oct 05 07:49 PM
Maduck Sean	See Remarks	Oct 01 '26	Option Exercise	8.27	413	3,416	10,351	Oct 05 07:49 PM
Maduck Sean	See Remarks	Oct 02 '26	Sale	116.28	24,587	2,858,884	9,938	Oct 05 07:49 PM
Maduck Sean	See Remarks	Oct 01 '26	Sale	115.54	413	47,717	9,938	Oct 05 07:49 PM
Lyon Joseph Douglas	Officer	Oct 01 '26	Proposed Sale	115.23	10,000	1,152,300		Oct 01 11:09 AM
Vieira Roberto Wandenkolk	President, Oncology	Sep 16 '26	Sale	100.82	296	29,843	3,946	Sep 18 07:53 PM
Robb Gary Charles	Chief Business Officer	Sep 17 '26	Option Exercise	8.27	17,493	144,667	31,156	Sep 18 07:47 PM
Lyon Joseph Douglas	See Remarks	Sep 14 '26	Option Exercise	12.99	10,000	129,863	15,683	Sep 16 04:30 PM
Lyon Joseph Douglas	See Remarks	Sep 14 '26	Sale	113.49	10,000	1,134,947	5,683	Sep 16 04:30 PM
WILSON JAMES N	Director	Sep 15 '26	Sale	110.69	10,000	1,106,940	1,064,543	Sep 16 04:30 PM
WILSON JAMES N	Director	Sep 15 '26	Proposed Sale	111.48	30,000	3,344,400		Sep 15 10:23 AM
Lyon Joseph Douglas	Officer	Sep 14 '26	Proposed Sale	113.44	10,000	1,134,424		Sep 14 01:58 PM
Maduck Sean	See Remarks	Sep 01 '26	Option Exercise	8.27	25,000	206,750	34,755	Sep 03 09:16 PM
Maduck Sean	See Remarks	Sep 01 '26	Sale	114.43	25,000	2,860,737	9,755	Sep 03 09:16 PM
Vieira Roberto Wandenkolk	President, Oncology	Sep 02 '26	Option Exercise	21.63	58,333	1,261,743	62,575	Sep 03 09:02 PM
Vieira Roberto Wandenkolk	President, Oncology	Sep 02 '26	Sale	110.76	58,333	6,460,766	4,242	Sep 03 09:02 PM
Vieira Roberto Wandenkolk	Officer	Sep 02 '26	Proposed Sale	110.76	75,295	8,339,418		Sep 02 04:08 PM
Park Kimberly	Director	Aug 26 '26	Option Exercise	13.49	30,000	404,700	30,000	Aug 28 04:30 PM
Park Kimberly	Director	Aug 26 '26	Sale	122.55	26,685	3,270,169	0	Aug 28 04:30 PM
Maduck Sean	See Remarks	Aug 25 '26	Option Exercise	11.35	30,955	351,339	40,710	Aug 27 04:30 PM
Maduck Sean	See Remarks	Aug 25 '26	Sale	125.58	30,955	3,887,320	9,755	Aug 27 04:30 PM
KIMBERLY PARK	Director	Aug 26 '26	Proposed Sale	122.55	26,685	3,270,169		Aug 26 04:14 PM
Maduck Sean	Officer	Aug 25 '26	Proposed Sale	125.58	175,000	21,976,448		Aug 25 05:24 PM
MAHONEY DAVID L	Director	Aug 18 '26	Sale	118.25	103,606	12,251,411	1,133,539	Aug 20 04:30 PM
Maduck Sean	See Remarks	Aug 14 '26	Option Exercise	8.27	3,664	30,301	13,419	Aug 18 04:30 PM
Maduck Sean	See Remarks	Aug 14 '26	Sale	114.49	3,664	419,491	9,755	Aug 18 04:30 PM
WILSON JAMES N	Director	Aug 14 '26	Sale	111.43	10,000	1,114,261	1,074,543	Aug 18 04:30 PM
Robb Gary Charles	Chief Business Officer	Aug 17 '26	Sale	116.26	10,000	1,162,572	39,716	Aug 18 04:30 PM
MAHONEY DAVID L	Director	Aug 18 '26	Proposed Sale	117.37	103,606	12,160,257		Aug 18 10:12 AM
Robb Gary Charles	Officer	Aug 17 '26	Proposed Sale	116.26	10,000	1,162,572		Aug 17 04:05 PM
Maduck Sean	See Remarks	Aug 10 '26	Option Exercise	8.27	1,031	8,526	10,786	Aug 12 04:27 PM
Maduck Sean	See Remarks	Aug 10 '26	Sale	114.52	1,031	118,068	9,755	Aug 12 04:27 PM
Guyer William	Chief Development Officer	Aug 10 '26	Option Exercise	21.65	16,300	352,895	20,285	Aug 12 04:26 PM
Guyer William	Chief Development Officer	Aug 10 '26	Sale	113.43	16,300	1,848,890	3,985	Aug 12 04:26 PM
Guyer William	Chief Development Officer	Aug 04 '26	Option Exercise	21.65	3,700	80,105	7,685	Aug 06 06:44 PM
Guyer William	Chief Development Officer	Aug 04 '26	Sale	113.12	3,700	418,562	3,985	Aug 06 06:44 PM
Maduck Sean	See Remarks	Aug 03 '26	Option Exercise	8.27	20,305	167,922	30,060	Aug 05 05:51 PM
Maduck Sean	See Remarks	Aug 03 '26	Sale	114.70	20,305	2,329,075	9,755	Aug 05 05:51 PM
Lyon Joseph Douglas	See Remarks	Aug 03 '26	Sale	114.16	1,540	175,806	5,495	Aug 05 05:48 PM
Guyer William	Officer	Aug 04 '26	Proposed Sale	112.80	20,000	2,256,000		Aug 04 03:07 PM
Mokari Atabak	Chief Financial Officer	Jul 30 '26	Option Exercise	23.06	80,000	1,844,800	96,130	Aug 03 04:30 PM
Mokari Atabak	Chief Financial Officer	Jul 30 '26	Sale	114.71	80,000	9,177,109	16,130	Aug 03 04:30 PM
Lyon Joseph Douglas	Officer	Aug 03 '26	Proposed Sale	114.16	1,540	175,806		Aug 03 12:16 PM
Mokari Atabak	Officer	Jul 30 '26	Proposed Sale	114.71	40,000	4,588,556		Jul 30 04:03 PM
WILSON JAMES N	Director	Jul 15 '26	Sale	88.30	10,000	882,986	1,084,543	Jul 17 06:38 PM
Mokari Atabak	Chief Financial Officer	Jul 15 '26	Option Exercise	21.56	40,000	862,235	56,130	Jul 17 06:31 PM
Mokari Atabak	Chief Financial Officer	Jul 15 '26	Sale	87.71	40,000	3,508,277	16,130	Jul 17 06:31 PM
Guyer William	Chief Development Officer	Jul 07 '26	Option Exercise	21.65	20,000	433,000	23,985	Jul 08 07:54 PM
Guyer William	Chief Development Officer	Jul 07 '26	Sale	93.13	20,000	1,862,530	3,985	Jul 08 07:54 PM
Guyer William	Officer	Jul 07 '26	Proposed Sale	93.13	20,000	1,862,530		Jul 07 11:12 AM
Maduck Sean	See Remarks	Jul 01 '26	Option Exercise	8.27	25,000	206,750	34,755	Jul 06 04:44 PM
Maduck Sean	See Remarks	Jul 01 '26	Sale	88.35	25,000	2,208,737	9,755	Jul 06 04:44 PM
WILSON JAMES N	Director	Jun 16 '26	Sale	83.20	10,000	832,049	1,094,543	Jun 18 04:30 PM
MAHONEY DAVID L	Director	Jun 17 '26	Sale	84.53	20,000	1,690,506	26,147	Jun 18 04:30 PM
Mokari Atabak	Chief Financial Officer	Jun 15 '26	Option Exercise	19.26	40,000	770,400	56,130	Jun 17 04:30 PM
Mokari Atabak	Chief Financial Officer	Jun 15 '26	Sale	81.15	40,000	3,245,900	16,130	Jun 17 04:30 PM
MAHONEY DAVID L	Director	Jun 16 '26	Proposed Sale	83.34	20,000	1,666,800		Jun 16 03:06 PM
WILSON JAMES N	Director	Jun 16 '26	Proposed Sale	83.20	30,000	2,496,147		Jun 16 01:55 PM
Guyer William	Chief Development Officer	Jun 02 '26	Option Exercise	21.65	20,000	433,000	23,985	Jun 04 04:49 PM
Guyer William	Chief Development Officer	Jun 02 '26	Sale	70.60	20,000	1,412,000	3,985	Jun 04 04:49 PM
Maduck Sean	See Remarks	Jun 01 '26	Option Exercise	8.27	25,000	206,750	33,977	Jun 03 07:20 PM
Maduck Sean	See Remarks	Jun 01 '26	Sale	70.21	25,000	1,755,183	8,977	Jun 03 07:20 PM
Mokari Atabak	Chief Financial Officer	Jun 01 '26	Option Exercise	19.26	40,000	770,400	55,257	Jun 03 07:20 PM
Mokari Atabak	Chief Financial Officer	Jun 01 '26	Sale	70.00	40,000	2,800,004	15,257	Jun 03 07:20 PM
BELANOFF JOSEPH K	Chief Executive Officer	Jun 01 '26	Sale	69.74	12,837	895,252	2,565,489	Jun 02 04:05 PM
Guyer William	Officer	Jun 02 '26	Proposed Sale	70.44	20,000	1,408,800		Jun 02 02:25 PM
Mokari Atabak	Officer	Jun 01 '26	Proposed Sale	70.00	160,000	11,200,016		Jun 01 05:50 PM
BELANOFF JOSEPH K	Officer	Jun 01 '26	Proposed Sale	69.49	12,837	892,043		Jun 01 11:40 AM
Lyon Joseph Douglas	See Remarks	May 27 '26	Sale	65.00	5,000	325,000	6,230	May 29 06:11 PM
Maduck Sean	See Remarks	May 27 '26	Option Exercise	8.27	75,000	620,250	83,977	May 29 06:03 PM
Maduck Sean	See Remarks	May 27 '26	Sale	65.59	75,000	4,918,944	8,977	May 29 06:03 PM
Maduck Sean	Officer	May 27 '26	Proposed Sale	65.59	150,000	9,837,900		May 27 06:07 PM
Lyon Joseph Douglas	Officer	May 20 '26	Proposed Sale	58.22	5,000	291,100		May 20 12:46 PM
Guyer William	Chief Development Officer	May 05 '26	Option Exercise	21.65	20,000	433,000	22,231	May 07 04:30 PM
Guyer William	Chief Development Officer	May 05 '26	Sale	51.83	20,000	1,036,600	2,231	May 07 04:30 PM
BELANOFF JOSEPH K	Chief Executive Officer	May 01 '26	Sale	50.10	40,000	2,003,860	2,878,326	May 05 04:30 PM
Guyer William	Officer	May 05 '26	Proposed Sale	51.60	20,000	1,032,000		May 05 11:13 AM
BELANOFF JOSEPH K	Officer	May 01 '26	Proposed Sale	46.52	40,000	1,860,800		May 01 12:30 PM
Guyer William	Chief Development Officer	Apr 07 '26	Option Exercise	21.65	20,000	433,000	22,231	Apr 08 07:34 PM
Guyer William	Chief Development Officer	Apr 07 '26	Sale	40.97	20,000	819,400	2,231	Apr 08 07:34 PM
Guyer William	Officer	Apr 07 '26	Proposed Sale	40.85	20,000	817,000		Apr 07 12:08 PM
BELANOFF JOSEPH K	Chief Executive Officer	Mar 25 '26	Sale	50.07	26,198	1,311,826	2,918,326	Mar 27 04:27 PM
BELANOFF JOSEPH K	Officer	Mar 25 '26	Proposed Sale	33.82	40,000	1,352,800		Mar 25 03:49 PM
Guyer William	Chief Development Officer	Mar 20 '26	Option Exercise	21.65	11,767	254,756	13,998	Mar 24 04:54 PM
Guyer William	Chief Development Officer	Mar 20 '26	Sale	36.01	11,767	423,730	2,231	Mar 24 04:54 PM
BAKER G LEONARD JR	Director	Mar 17 '26	Buy	33.14	100,000	3,313,809	1,146,631	Mar 19 05:07 PM
MAHONEY DAVID L	Director	Mar 13 '26	Option Exercise	5.86	30,000	175,800	30,000	Mar 17 07:52 PM
Guyer William	Chief Development Officer	Mar 04 '26	Option Exercise	21.65	8,233	178,244	10,464	Mar 06 04:30 PM
Guyer William	Chief Development Officer	Mar 04 '26	Sale	35.99	8,233	296,346	2,231	Mar 06 04:30 PM
Guyer William	Officer	Mar 04 '26	Proposed Sale	35.28	20,000	705,600		Mar 04 04:02 PM
WILSON JAMES N	Director	Feb 24 '26	Option Exercise	3.88	100,000	388,000	100,000	Feb 26 04:45 PM
Hunt Hazel	Chief Scientific Officer	Feb 09 '26	Option Exercise	3.88	150,000	582,000	333,405	Feb 11 05:26 PM
Guyer William	Chief Development Officer	Feb 03 '26	Option Exercise	21.65	20,000	433,000	21,235	Feb 05 05:42 PM

Corcept Therapeutics, Inc. engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Co-FounderDr. Joseph K. Belanoff M.D.

CFO & TreasurerMr. Atabak Mokari

Chief Development OfficerDr. William Guyer Pharm.D.

Chief Business Officer & SecretaryMr. Gary Charles Robb J.D.

Chief Technology & Accounting OfficerMr. Joseph Douglas Lyon

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CORT

Corcept Therapeutics Inc

Upgrade your Finviz experience